Oasis Submits Shareholder Proposals to Kobayashi Pharmaceutical for 2026 AGM

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Akihiro Kobayashi has taken on additional responsibilities beyond victim compensation, such as serving on the executive Compensation Committee, deviating from the original reasons for his selection.

  80% confidence

• Corporate governance reforms at Kobayashi Pharmaceutical are not yet complete, with the company continuing to be overly influenced by the founding family.

  80% confidence

• Oasis's proposals aim to reduce founding family influence through multiple layers of measures that strengthen corporate governance in line with management's wishes.

  80% confidence

• Oasis is the largest shareholder of Kobayashi Pharmaceutical, beneficially owning over 13.1% of the company.

  80% confidence

• Akihiro Kobayashi was one of the root causes of the Beni-Koji incident and continues to exert influence on Kobayashi Pharmaceutical, preventing the company from breaking free from founding family influences.

  80% confidence

• Yoshiro Katae's expertise in crisis management and compliance was not meaningfully applied, contributing to the escalation of harm in the Beni-Koji incident.

  80% confidence

• Kobayashi Pharmaceutical has not yet been able to fully break free from the influences of the Kobayashi Family, who were one of the major causes of the slow response to the Beni-Koji incident.

  80% confidence

• Hitoshi Kawaguchi will provide particularly valuable oversight regarding management's execution of duties concerning establishment and operation of internal control systems.

  80% confidence

• Improved quality assurance measures have not been fully implemented at Kobayashi Pharmaceutical, as evident from a recent product recall.

  80% confidence

Cited in these Via News reports

• Private Equity Consortium Pays $12.5 Billion for AES Corporation in Largest US Energy Infrastructure Deal Since 2021 →